← back to search

Zhongqiu Lin

Sun Yat-sen University · CN
Area of research
Epidemiology · Reproductive Medicine
Research interest
Research interests include Cervical Cancer and HPV Research, Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, and Reproductive tract infections research.
h-index
14
citations
886
works
64
NIH funding
primary concept
email

Recent publications

453 Senaparib maintenance in newly diagnosed advanced ovarian cancer: FLAMES study
International Journal of Gynecological Cancer 2024cited by 1position: middledoi
LBA36 Efficacy and safety of senaparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer (FLAMES study): A randomized, double-blind, placebo-controlled, phase III trial
Annals of Oncology 2023cited by 3position: middledoi
[Evaluation of the efficacy and safety of Nocardia rubra cell wall skeleton immunotherapy for cervical high-risk HPV persistent infection].
PubMed 2023cited by 2position: middledoi
765P SABRINA study: A phase II study of senaparib monotherapy for patients (pts) with BRCA1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC)
Annals of Oncology 2023cited by 1position: middledoi
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
Journal of Clinical Oncology 2022cited by 72position: middledoi
Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
Clinical Cancer Research 2021cited by 37position: middledoi
High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery 2021cited by 28position: middledoi
820P Phase II study of pamiparib in Chinese patients (pts) with advanced ovarian cancer (aOC)
Annals of Oncology 2020cited by 2position: middledoi
Downregulation of long noncoding RNA MEG3 is associated with poor prognosis and promoter hypermethylation in cervical cancer
Journal of Experimental & Clinical Cancer Research 2017cited by 127position: middledoi
Aberrant Methylation of MEG3 Functions as a Potential Plasma-Based Biomarker for Cervical Cancer
Scientific Reports 2017cited by 80position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jianqing Zhu · Huaqiao University5 papers (2020–2024)Yi Huang · Shandong Center for Disease Control and Prevention4 papers (2020–2023)Beihua Kong · Chinese Center For Disease Control and Prevention4 papers (2020–2023)Jing Wang · Sun Yat-sen University Cancer Center4 papers (2021–2024)Jihong Liu · Sun Yat-sen University3 papers (2023–2024)Ge Lou · Harbin Medical University3 papers (2020–2024)Xiaohua Wu · Shanghai Medical College of Fudan University3 papers (2023–2024)K. Wang · Chunghwa Telecom (Taiwan)2 papers (2023–2023)Hong Zheng · Fujian Medical University2 papers (2023–2024)Xiaohua Wu · Fujian Medical University2 papers (2020–2021)Wei Sun · Third Affiliated Hospital of Guangzhou Medical University2 papers (2020–2021)Ge Lou · Harbin Medical University2 papers (2021–2023)Zhiyong Liang · Affiliated Hospital of Guizhou Medical University2 papers (2023–2023)Ying Cheng · Verizon (United States)2 papers (2020–2021)Qi Zhou · University Medical Center Groningen2 papers (2020–2021)Jun Zhang · Ningbo University of Technology2 papers (2017–2017)Kui Jiang · Dalian Medical University2 papers (2023–2024)Yali Gao · Shanghai University2 papers (2017–2017)Xiyan Mu · North West Agriculture and Forestry University2 papers (2020–2021)Shuzhong Yao · Central South University1 papers (2023–2023)